Celgene Corp (CELG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
382
About the Report
About the Report
Summary
Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaza (azacitidine) for the treatment of myelodysplastic syndromes (MDS); Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancers; Otezla (apremilast) for psoriatic arthritis; and Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL) and Peripheral T-cell lymphoma (PTCL). The company also has several products in various stages of development for the treatment of hematological and solid tumor cancers. It has manufacturing facilities in Boudry and Zofingen in Switzerland; and Arizona, the US. The company sells its products through own sales organizations and distributors in the Americas, Europe, the Middle-East and Asia-Pacific. Celgene is headquartered in Summit, New Jersey, the US.
Celgene Corp (CELG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Celgene Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 9
List of Figures 12
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14
Celgene Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 15
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 17
Celgene Corp, Medical Devices Deals, 2012 to YTD 2018 19
Celgene Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 20
Celgene Corp, Pharmaceuticals & Healthcare, Deal Details 35
Asset Purchase 35
Impact Biomedicines Acquires Rights for Fedratinib from Sanofi 35
Celgene Enters into Option Agreement to Acquire Assets of TRPH-222 from Triphase Accelerator 36
Celgene Acquires Marizomib from Triphase Accelerator 37
Celgene Enters into Option to Acquire VEGFR-2/TIE 2 Bi-Specific Antibody from Triphase 38
Celgene To Acquire Romidepsin Injection Patents From Cyclacel For USD 5.5 Million 39
Venture Financing 41
Gotham Therapeutics Raises USD54 Million in Series A Financing 41
Silverback Therapeutics Raises USD37.5 Million in Series A Venture Financing 43
Sutro Biopharma Raises USD85.4 Million in Series E Financing 44
Nohla Therapeutics Raises Additional USD11 Million in Second Tranche of Series B Venture Financing 46
Nohla Therapeutics Raises USD45 Million in Series B Venture Financing 48
Cyteir Therapeutics Raises USD29 Million in Series B Financing 50
JW Therapeutics Raises USD90 Million in Series A Financing 52
Celularity Raises USD250 Million in Venture Financing 53
FLX Bio Raises USD60 Million in Series C Financing 55
Arcus Biosciences Raises USD107 Million in Series C Financing 57
Impact Biomedicines Raises USD22 Million in Series A Financing 59
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 60
Evelo Biosciences Raises USD50 Million in Series B Financing 62
Repare Therapeutics Raises USD68 million in Series A Financing 64
Dragonfly Therapeutics Raises Funds through Venture Financing 65
Aadi Bioscience Raises USD23 Million in Series A Venture Financing 66
Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 67
Oncorus Raises Additional USD4 Million in Series A Financing 69
Delinia Raises USD35 Million in Series A Financing 70
Cleave Biosciences Raises USD37 Million in Series B Financing Round 71
Oncorus Raises USD57 Million in Series A Financing Round 73
Sapience Therapeutics Raises USD22.5 Million in Series A Financing 74
Agenovir Raises USD10.6 Million in Series A Venture Financing 75
Ideaya Biosciences Raises USD46 Million in Series A Financing 76
FLX Bio Raises USD50 Million in Series B Financing 78
AbViro Raises USD0.4 Million in Venture Financing 80
Armo Biosciences Raises USD50 Million in Series C Financing 81
Zymeworks Raises USD61.5 Million in Series A Financing 83
Flatiron Health Raises USD175 Million in Series C Financing 85
Cyteir Therapeutics Raises USD5.5 Million in Series A Financing 87
Arcus Biosciences Raises USD50 Million in Series A Financing 88
Mirna Therapeutics Raises USD41.8 Million in Series D Financing 90
CRISPR Therapeutics Raises USD29 Million in Series B Financing 92
CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 94
Flexus Biosciences Raises USD25 Million in Series B Venture Financing 96
VentiRx Pharma Raises USD15 Million in Venture Financing 97
VentiRx Pharmaceuticals Secures USD50.6 Million in Venture Funding 98
Juno Therapeutics Raises USD134 Million in Series B Financing 99
Juno Therapeutics Raises USD 31 Million In Extended Series A Financing 100
Juno Therapeutics Raises USD 145 Million In Series A Financing 101
Atara Biotherapeutics Raises USD 52 Million In Series B Financing 103
Sutro Biopharma Raises USD 26 Million In Series D Financing 105
Flexus Biosciences Raises USD13 Million in Series A Venture Financing 107
Acetylon Pharmaceuticals Secures USD100 Million in Fundnig from Celgene 108
PTC Therapeutics Raises USD 60 Million In Venture Financing 109
PharmAkea Raises Funds Through Seed Financing 111
Ptc Therapeutics Raises USD 30 Million In Venture Financing 112
AbVitro Raises USD 0.75 Million In Venture Financing 114
AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 115
Acetylon Pharma Raises USD 15 Million From Celgene 116
X-BODY Raises Additional USD 0.6 Million In Venture Financing 117
Private Equity 118
Oberland Capital Invests USD90 Million in Impact Biomedicines 118
Celgene to Reject Mini Tender Offer by TRC Capital 119
Partnerships 120
Evotec and Celgene Enter into Partnership 120
Skyhawk Therapeutics Enters into Collaboration Agreement with Celgene 121
Evotec and Celgene Enter into Drug Discovery and Development Partnership 122
Northern Biologics Enters into R&D Agreement with Celgene 123
Celgene and Bluebird Enter into Co-Development Agreement 124
Prothena Biosciences Enters into R&D Agreement with Celgene Switzerland 125
Vividion Therapeutics Enters into Research Agreement with Celgene 127
Cancer Research Technology Enters into Partnership with Celgene 128
Nimbus Therapeutics Enters into Agreement with Celgene 129
Celgene and BeiGene Enters into Partnership 130
Celgene Enters into Agreement with Forma Therapeutics 131
Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 132
Dragonfly Therapeutics Enters into Agreement with Celgene 133
IMIDomics Enters into Agreement with Celgene 134
Celgene Enters into Research Agreement with Anokion 135
Evotec Expands Research Agreement with Celgene 136
Celgene Enters into Agreement with IBM Watson Health 137
Celgene Enters into Agreement with Jounce Therapeutics 138
Celgene Enters into Co-Development Agreement with Sidney Kimmel Comprehensive Cancer Center 139
Celgene Enters into Co-Development Agreement with Tisch Cancer Institute 140
Celgene Enters into Co-Development Agreement with Abramson Cancer Center 141
Celgene Enters into Co-Development Agreement with Herbert Irving Comprehensive Cancer Center 142
Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 143
TriNetX Partners with Celgene 144
Agios Pharma Enters into Co-Development Agreement with Celgene 145
Flatiron Health Partners with Celgene 146
Juno Therapeutics Forms Joint Venture with WuXi AppTec 147
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 148
Hereditary Neuropathy Foundation Partners with Acetylon Pharma 149
Inception IBD Enters into Agreement with Celgene 150
Nurix Enters into Co-Development Agreement with Celgene 151
Celgene Partners with Recombinant Antibody Network 152
Celgene Exercises Option Agreement with Juno Therapeutics 153
Lycera Enters into Co-Development Agreement with Celgene 154
Juno Therapeutics Enters into Research Agreement with Editas Medicine 155
Cypher Genomics Enters into Co-Development Agreement with Celgene 156
Adimab Enters into Discovery Agreement with Celgene 157
Celgene Enters into Co-Development Agreement with MedImmune 158
MedImmune Enters into Agreement with Juno Therapeutics 159
Sutro Biopharma Amends Co-Development Agreement with Celgene 160
Bristol-Myers Squibb Enters into Agreement with Celgene 162
NanoString Enters into Co-Development Agreement with Celgene 163
Abide Therapeutics Enters Into Drug Discovery Agreement With Celgene 164
OncoMed Pharma Enters Into Co-Development Agreement With Celgene 165
Juno Therapeutics Enters into Research Agreement with FHCRC 167
PharmAkea Therapeutics Extends Agreement with Celgene 168
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 169
Concert Pharma Enters Into Co-Development Agreement With Celgene 170
Forma Therapeutics Partners With Celgene 171
X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 172
Forma Therapeutics Enters Into Agreement With Celgene 173
bluebird bio Amends Co-Development Agreement With Celgene 175
Presage Biosciences Enters Into Research Agreement With Celgene 176
Triphase Accelerator Enters Into Co-Development Agreement With Celgene 177
Triphase Expands Co-Development Agreement with Celgene 178
Sutro Biopharma Enters Into Co-Development Agreement With Celgene 180
Celgene And PharmAria Enters Into Agreement To Discover Small-Molecule Therapeutic Targets 181
VentiRx Pharma Enters Into Agreement With Celgene To Develop TLR8 Agonist VTX-2337 182
Advinus Therapeutics Enters Into R&D Agreement With Celgene Global Health For Visceral Leishmaniasis 183
Licensing Agreements 184
Celgene Enters into Licensing Agreement with Abide Therapeutics 184
Celgene Enters into Licensing Agreement with Amunix Operating 185
Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 186
Juno Therapeutics Enters into Licensing Agreement with Oncotracker 187
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 188
Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 189
Acceleron Pharma Enters into Licensing Agreement with Celgene 190
BeiGene Enters into Licensing Agreement with Celgene 192
Antengene Enters into Licensing Agreement with Celgene 193
Regenacy Pharma Receives Rights to HDAC6 Inhibitor, Ricolinostat ACY-1215 from Acetylon Pharma 194
Celgene Enters into Licensing Agreement with GNS Healthcare 195
MetaStat Amends Licensing Agreement with Celgene 196
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 197
Celgene Exercises Option for Licensing Agreement with Lycera 198
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 199
Celgene Exercises Option for Licensing Agreement with GlobeImmune 200
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 201
Open Monoclonal Enters into Licensing Agreement with Celgene 203
Celgene Exercises Licensing Agreement with Zymeworks for Bi-Specific Antibody 204
Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 205
Moffitt Cancer Center Enters into Licensing Agreement with Celgene 206
Vernalis Enters into Licensing Agreement with RedoxTherapies 207
AADi Enters into Licensing Agreement with Celgene for ABI-009 208
Celgene Enters into Licensing Agreement with Nogra Pharma for GED 0301 209
NantBioScience Enters Into Licensing Agreement With Celgene To Develop Cancer Therapies 211
Juno Therapeutics Enters into Licensing Agreement with St. Jude Children’s Research Hospital 212
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 213
Juno Therapeutics Enters into Licensing Agreement with FHCRC 214
Celgene Enters into Licensing Agreement with Baylor College of Medicine 215
Inhibrx Enters into Licensing Agreement with Celgene 216
Epizyme Amends Licensing Agreement with Celgene for HMT Inhibitor Programs 217
Juno Therapeutics Enters into Licensing Agreement with Trianni 219
Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 220
Celgene Enters into Licensing Agreement with Juno Therapeutics 221
Agios Pharma Exercises Option For Licensing Agreement With Celgene 222
Equity Offering 224
Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 224
Celularity Spins Out from Celgene 226
Jounce Therapeutics Raises USD139 Million in Private Placement of Shares 227
NantKwest Raises USD17 Million in Private Placement of Shares 228
Mesoblast Raises USD44.8 Million in Private Placement of Shares 229
Juno Therapeutics Raises USD304 Million in IPO 230
Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 232
Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 233
Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 234
Acceleron Pharma Completes Private Placement Of Shares For USD 10 Million 235
Debt Offering 237
Celgene Raises USD500 Million in Public Offering of 2.875% Notes Due 2021 237
Celgene Raises USD1 Billion in Public Offering of 3.25% Notes Due 2023 239
Celgene Raises USD1.5 Billion in Public Offering of 4.55% Notes Due 2048 241
Celgene Raises USD1.5 Billion in Public Offering of 3.9% Notes Due 2028 243
Celgene Prices USD750 Million in Public Offering of 2.750% Notes Due 2023 245
Celgene Prices USD1,000 Million in Public Offering of 3.450% Notes Due 2027 246
Celgene Prices USD1,250 Million in Public Offering of 4.350% Notes Due 2047 247
Celgene Raises USD500 Million in Public Offering of 2.25% Notes Due 2021 248
Celgene Prices Public Offering of 5% Notes Due 2045 for USD2 Billion 249
Celgene Prices Public Offering of 3.55% Notes Due 2022 for USD1 Billion 251
Celgene Prices Public Offering of 2.125% Notes Due 2018 for USD1 Billion 253
Celgene Prices Public Offering of 2.875% Notes Due 2020 for USD1.5 Billion 255
Celgene Prices Public Offering of 3.875% Notes Due 2025 for USD2.5 Billion 257
Celgene Completes Public Offering Of Notes Due 2044 For USD1 Billion 259
Celgene Completes Public Offering Of Notes Due 2019 For USD500 Million 261
Celgene Completes Public Offering Of Notes Due 2024 For USD1 Billion 263
Celgene Completes Public Offering Of Notes Due 2018 For USD 400 Million 265
Celgene Completes Public Offering Of Notes Due 2043 For USD 400 Million 266
Celgene Completes Public Offering Of Notes Due 2023 For USD 700 Million 267
Tengion Completes Private Placement Of Notes Due 2015 For USD 15 Million 268
Celgene Completes Public Offering Of Senior Unsecured Notes Due 2022 For USD 1 Billion 270
Celgene Completes Public Offering Of Senior Unsecured Notes Due 2017 For USD 500 Million 271
Asset Transactions 272
Roche Acquires PETE Technology from AbVitro 272
Acquisition 273
Celgene Acquires Juno Therapeutics for USD9 Billion 273
Celgene Acquires Impact Biomedicines for up to USD7 Billion 275
Celgene to Acquire 5.9% Stake in BeiGene for USD150 Million 276
Celgene Acquires VentiRx Pharma 277
Celgene to Acquire Delinia 278
Celgene Acquires Acetylon Pharma 279
Celgene Acquires EngMab 280
Juno Therapeutics Acquires RedoxTherapies 281
Juno Therapeutics Acquires AbVitro 282
Celgene Acquires Receptos for USD7.2 Billion 283
Juno Therapeutics Acquires X-BODY 285
AstraZeneca May Acquire Juno Therapeutics 286
Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 287
Celgene to Acquire Quanticel Pharma for USD485 Million 288
Juno Therapeutics Acquires ZetaRx BioSciences 289
Celgene To Acquire Stake In PharmAkea Therapeutics 290
Celgene Invests USD 15 Million In Tengion 291
Celgene Completes Acquisition Of Avila Therapeutics 292
Celgene Corp - Key Competitors 293
Celgene Corp - Key Employees 294
Celgene Corp - Locations And Subsidiaries 295
Head Office 295
Other Locations & Subsidiaries 295
Recent Developments 300
Strategy And Business Planning 300
May 24, 2018: Prothena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline 300
Financial Announcements 301
Oct 25, 2018: Celgene Reports Third Quarter 2018 Operating and Financial Results 301
Jul 26, 2018: Celgene Reports Second Quarter 2018 Operating and Financial Results 309
May 04, 2018: Celgene Reports First Quarter 2018 Operating and Financial Results 311
Jan 25, 2018: Celgene Reports Fourth Quarter and Full-Year 2017 Operating and Financial Results 314
Jan 08, 2018: Celgene Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance 317
Oct 26, 2017: Celgene Reports Third Quarter 2017 Operating and Financial Results 319
Jul 27, 2017: Celgene Reports Second Quarter 2017 Operating and Financial Results 321
Apr 27, 2017: Celgene Reports First Quarter 2017 Operating and Financial Results 324
Jan 26, 2017: Celgene Reports Fourth Quarter and Full-Year 2016 Operating and Financial Results 326
Jan 09, 2017: Celgene Announces Preliminary 2016 Unaudited Results And 2017 Financial Guidance 329
Corporate Communications 331
Oct 22, 2018: Celgene announces appointment of Dr. Alise Reicin to president, global clinical development 331
May 31, 2018: Celgene Announces Hiring of David V. Elkins as Executive Vice President, Chief Financial Officer and Appointment of Peter N. Kellogg to Executive Vice President, Chief Corporate Strategy Officer 332
Apr 30, 2018: Celgene Names Jennifer Dudinak As Senior Vice President Of Global Regulatory Affairs 333
Apr 19, 2018: Celgene Announces Changes to Its Board of Directors 334
Apr 02, 2018: Celgene Announces Departure of President and Chief Operating Officer Scott A. Smith 335
Feb 15, 2018: Celgene Names John Weiland As Board Director 336
Dec 29, 2017: Celgene Announces Retirement of Executive Chairman Bob Hugin and Appointment of CEO Mark Alles as Chairman of the Board of Directors 337
Feb 23, 2017: Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer 338
Legal and Regulatory 339
Aug 03, 2017: Multimillion Settlement with Biopharmaceutical Company 339
Government and Public Interest 340
May 17, 2018: ASCO 2018 Preview Precision Medicine, CAR T Cells and Immunomodulators 340
Mar 21, 2018: Leukemia Patient's Legacy Helps Drive Innovative Cancer Clinical Trial 342
Dec 05, 2017: Bioethics International Releases the "Good Pharma Scorecard" in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency 344
Product News 345
11/27/2017: Impact Biomedicines to Present Retrospective Data on Fedratinib at the 2017 ASH Annual Meeting 345
11/01/2017: Agios to Present New Data on IDH Program at the 2017 ASH Annual Meeting 346
Aug 24, 2018: Building on research on immunomodulator regimens in relapsed multiple myeloma treatment 347
08/01/2017: FDA Grants Approval Of IDHIFA, The First Oral Targeted Therapy For Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia And An IDH2 Mutation 349
06/24/2017: New Data from Phase 1/2 Trial of Oral IDHIFA (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML 351
06/06/2017: Precision therapy enasidenib effective in treating deadly form of leukemia 353
Apr 05, 2018: FORMA Therapeutics Achieves Key Objective in Collaboration with Celgene to Advance a Novel Protein Homeostasis Oncology/Immuno-Oncology Program 354
03/01/2017: FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation 355
Product Approvals 356
Feb 27, 2018: Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis 356
Clinical Trials 357
Apr 24, 2018: New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting 357
Dec 11, 2017: Agios Pharma Presents Data From Two Studies Evaluating Investigational Use of Enasidenib at 59th American Society of Hematology Annual Meeting in Atlanta 359
Dec 11, 2017: Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials 361
Nov 09, 2017: Ozanimod Successful in Clinical Trials for Multiple Sclerosis 362
Oct 28, 2017: Efficacy and Safety Results from Second Phase III Trial (RADIANCE Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting 363
Oct 27, 2017: Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting 365
Oct 19, 2017: Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting 367
Oct 16, 2017: Results from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017 370
Sep 27, 2017: Promising results in clinical trial for aggressive form of leukaemia 372
Jun 14, 2017: Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus 373
Jun 06, 2017: Updated Data from Phase 1 Trial of Oral IDHIFA (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation 374
May 22, 2017: Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis 376
May 17, 2017: Agios to Present New Clinical Data from Phase 1 Study of Enasidenib at ASCO 378
Feb 21, 2017: TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis 379
Feb 17, 2017: Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis 380
Other Significant Developments 381
Dec 05, 2017: Celgene Launches Celgene Cancer Care Links to Support Cancer Healthcare Capacity Building in Resource-Constrained Countries 381
Appendix 382
Methodology 382
About GlobalData 382
Contact Us 382
Disclaimer 382
List of Figure
List of Figures
Celgene Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14
Celgene Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 15
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 17
Celgene Corp, Medical Devices Deals, 2012 to YTD 2018 19
List of Table
List of Tables
Celgene Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14
Celgene Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 15
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16
Celgene Corp, Deals By Therapy Area, 2012 to YTD 2018 17
Celgene Corp, Medical Devices Deals, 2012 to YTD 2018 19
Celgene Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 20
Impact Biomedicines Acquires Rights for Fedratinib from Sanofi 35
Celgene Enters into Option Agreement to Acquire Assets of TRPH-222 from Triphase Accelerator 36
Celgene Acquires Marizomib from Triphase Accelerator 37
Celgene Enters into Option to Acquire VEGFR-2/TIE 2 Bi-Specific Antibody from Triphase 38
Celgene To Acquire Romidepsin Injection Patents From Cyclacel For USD 5.5 Million 39
Gotham Therapeutics Raises USD54 Million in Series A Financing 41
Silverback Therapeutics Raises USD37.5 Million in Series A Venture Financing 43
Sutro Biopharma Raises USD85.4 Million in Series E Financing 44
Nohla Therapeutics Raises Additional USD11 Million in Second Tranche of Series B Venture Financing 46
Nohla Therapeutics Raises USD45 Million in Series B Venture Financing 48
Cyteir Therapeutics Raises USD29 Million in Series B Financing 50
JW Therapeutics Raises USD90 Million in Series A Financing 52
Celularity Raises USD250 Million in Venture Financing 53
FLX Bio Raises USD60 Million in Series C Financing 55
Arcus Biosciences Raises USD107 Million in Series C Financing 57
Impact Biomedicines Raises USD22 Million in Series A Financing 59
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 60
Evelo Biosciences Raises USD50 Million in Series B Financing 62
Repare Therapeutics Raises USD68 million in Series A Financing 64
Dragonfly Therapeutics Raises Funds through Venture Financing 65
Aadi Bioscience Raises USD23 Million in Series A Venture Financing 66
Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 67
Oncorus Raises Additional USD4 Million in Series A Financing 69
Delinia Raises USD35 Million in Series A Financing 70
Cleave Biosciences Raises USD37 Million in Series B Financing Round 71
Oncorus Raises USD57 Million in Series A Financing Round 73
Sapience Therapeutics Raises USD22.5 Million in Series A Financing 74
Agenovir Raises USD10.6 Million in Series A Venture Financing 75
Ideaya Biosciences Raises USD46 Million in Series A Financing 76
FLX Bio Raises USD50 Million in Series B Financing 78
AbViro Raises USD0.4 Million in Venture Financing 80
Armo Biosciences Raises USD50 Million in Series C Financing 81
Zymeworks Raises USD61.5 Million in Series A Financing 83
Flatiron Health Raises USD175 Million in Series C Financing 85
Cyteir Therapeutics Raises USD5.5 Million in Series A Financing 87
Arcus Biosciences Raises USD50 Million in Series A Financing 88
Mirna Therapeutics Raises USD41.8 Million in Series D Financing 90
CRISPR Therapeutics Raises USD29 Million in Series B Financing 92
CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 94
Flexus Biosciences Raises USD25 Million in Series B Venture Financing 96
VentiRx Pharma Raises USD15 Million in Venture Financing 97
VentiRx Pharmaceuticals Secures USD50.6 Million in Venture Funding 98
Juno Therapeutics Raises USD134 Million in Series B Financing 99
Juno Therapeutics Raises USD 31 Million In Extended Series A Financing 100
Juno Therapeutics Raises USD 145 Million In Series A Financing 101
Atara Biotherapeutics Raises USD 52 Million In Series B Financing 103
Sutro Biopharma Raises USD 26 Million In Series D Financing 105
Flexus Biosciences Raises USD13 Million in Series A Venture Financing 107
Acetylon Pharmaceuticals Secures USD100 Million in Fundnig from Celgene 108
PTC Therapeutics Raises USD 60 Million In Venture Financing 109
PharmAkea Raises Funds Through Seed Financing 111
Ptc Therapeutics Raises USD 30 Million In Venture Financing 112
AbVitro Raises USD 0.75 Million In Venture Financing 114
AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 115
Acetylon Pharma Raises USD 15 Million From Celgene 116
X-BODY Raises Additional USD 0.6 Million In Venture Financing 117
Oberland Capital Invests USD90 Million in Impact Biomedicines 118
Celgene to Reject Mini Tender Offer by TRC Capital 119
Evotec and Celgene Enter into Partnership 120
Skyhawk Therapeutics Enters into Collaboration Agreement with Celgene 121
Evotec and Celgene Enter into Drug Discovery and Development Partnership 122
Northern Biologics Enters into R&D Agreement with Celgene 123
Celgene and Bluebird Enter into Co-Development Agreement 124
Prothena Biosciences Enters into R&D Agreement with Celgene Switzerland 125
Vividion Therapeutics Enters into Research Agreement with Celgene 127
Cancer Research Technology Enters into Partnership with Celgene 128
Nimbus Therapeutics Enters into Agreement with Celgene 129
Celgene and BeiGene Enters into Partnership 130
Celgene Enters into Agreement with Forma Therapeutics 131
Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 132
Dragonfly Therapeutics Enters into Agreement with Celgene 133
IMIDomics Enters into Agreement with Celgene 134
Celgene Enters into Research Agreement with Anokion 135
Evotec Expands Research Agreement with Celgene 136
Celgene Enters into Agreement with IBM Watson Health 137
Celgene Enters into Agreement with Jounce Therapeutics 138
Celgene Enters into Co-Development Agreement with Sidney Kimmel Comprehensive Cancer Center 139
Celgene Enters into Co-Development Agreement with Tisch Cancer Institute 140
Celgene Enters into Co-Development Agreement with Abramson Cancer Center 141
Celgene Enters into Co-Development Agreement with Herbert Irving Comprehensive Cancer Center 142
Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 143
TriNetX Partners with Celgene 144
Agios Pharma Enters into Co-Development Agreement with Celgene 145
Flatiron Health Partners with Celgene 146
Juno Therapeutics Forms Joint Venture with WuXi AppTec 147
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 148
Hereditary Neuropathy Foundation Partners with Acetylon Pharma 149
Inception IBD Enters into Agreement with Celgene 150
Nurix Enters into Co-Development Agreement with Celgene 151
Celgene Partners with Recombinant Antibody Network 152
Celgene Exercises Option Agreement with Juno Therapeutics 153
Lycera Enters into Co-Development Agreement with Celgene 154
Juno Therapeutics Enters into Research Agreement with Editas Medicine 155
Cypher Genomics Enters into Co-Development Agreement with Celgene 156
Adimab Enters into Discovery Agreement with Celgene 157
Celgene Enters into Co-Development Agreement with MedImmune 158
MedImmune Enters into Agreement with Juno Therapeutics 159
Sutro Biopharma Amends Co-Development Agreement with Celgene 160
Bristol-Myers Squibb Enters into Agreement with Celgene 162
NanoString Enters into Co-Development Agreement with Celgene 163
Abide Therapeutics Enters Into Drug Discovery Agreement With Celgene 164
OncoMed Pharma Enters Into Co-Development Agreement With Celgene 165
Juno Therapeutics Enters into Research Agreement with FHCRC 167
PharmAkea Therapeutics Extends Agreement with Celgene 168
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 169
Concert Pharma Enters Into Co-Development Agreement With Celgene 170
Forma Therapeutics Partners With Celgene 171
X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 172
Forma Therapeutics Enters Into Agreement With Celgene 173
bluebird bio Amends Co-Development Agreement With Celgene 175
Presage Biosciences Enters Into Research Agreement With Celgene 176
Triphase Accelerator Enters Into Co-Development Agreement With Celgene 177
Triphase Expands Co-Development Agreement with Celgene 178
Sutro Biopharma Enters Into Co-Development Agreement With Celgene 180
Celgene And PharmAria Enters Into Agreement To Discover Small-Molecule Therapeutic Targets 181
VentiRx Pharma Enters Into Agreement With Celgene To Develop TLR8 Agonist VTX-2337 182
Advinus Therapeutics Enters Into R&D Agreement With Celgene Global Health For Visceral Leishmaniasis 183
Celgene Enters into Licensing Agreement with Abide Therapeutics 184
Celgene Enters into Licensing Agreement with Amunix Operating 185
Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 186
Juno Therapeutics Enters into Licensing Agreement with Oncotracker 187
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 188
Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 189
Acceleron Pharma Enters into Licensing Agreement with Celgene 190
BeiGene Enters into Licensing Agreement with Celgene 192
Antengene Enters into Licensing Agreement with Celgene 193
Regenacy Pharma Receives Rights to HDAC6 Inhibitor, Ricolinostat ACY-1215 from Acetylon Pharma 194
Celgene Enters into Licensing Agreement with GNS Healthcare 195
MetaStat Amends Licensing Agreement with Celgene 196
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 197
Celgene Exercises Option for Licensing Agreement with Lycera 198
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 199
Celgene Exercises Option for Licensing Agreement with GlobeImmune 200
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 201
Open Monoclonal Enters into Licensing Agreement with Celgene 203
Celgene Exercises Licensing Agreement with Zymeworks for Bi-Specific Antibody 204
Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 205
Moffitt Cancer Center Enters into Licensing Agreement with Celgene 206
Vernalis Enters into Licensing Agreement with RedoxTherapies 207
AADi Enters into Licensing Agreement with Celgene for ABI-009 208
Celgene Enters into Licensing Agreement with Nogra Pharma for GED 0301 209
NantBioScience Enters Into Licensing Agreement With Celgene To Develop Cancer Therapies 211
Juno Therapeutics Enters into Licensing Agreement with St. Jude Children’s Research Hospital 212
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 213
Juno Therapeutics Enters into Licensing Agreement with FHCRC 214
Celgene Enters into Licensing Agreement with Baylor College of Medicine 215
Inhibrx Enters into Licensing Agreement with Celgene 216
Epizyme Amends Licensing Agreement with Celgene for HMT Inhibitor Programs 217
Juno Therapeutics Enters into Licensing Agreement with Trianni 219
Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 220
Celgene Enters into Licensing Agreement with Juno Therapeutics 221
Agios Pharma Exercises Option For Licensing Agreement With Celgene 222
Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 224
Celularity Spins Out from Celgene 226
Jounce Therapeutics Raises USD139 Million in Private Placement of Shares 227
NantKwest Raises USD17 Million in Private Placement of Shares 228
Mesoblast Raises USD44.8 Million in Private Placement of Shares 229
Juno Therapeutics Raises USD304 Million in IPO 230
Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 232
Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 233
Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 234
Acceleron Pharma Completes Private Placement Of Shares For USD 10 Million 235
Celgene Raises USD500 Million in Public Offering of 2.875% Notes Due 2021 237
Celgene Raises USD1 Billion in Public Offering of 3.25% Notes Due 2023 239
Celgene Raises USD1.5 Billion in Public Offering of 4.55% Notes Due 2048 241
Celgene Raises USD1.5 Billion in Public Offering of 3.9% Notes Due 2028 243
Celgene Prices USD750 Million in Public Offering of 2.750% Notes Due 2023 245
Celgene Prices USD1,000 Million in Public Offering of 3.450% Notes Due 2027 246
Celgene Prices USD1,250 Million in Public Offering of 4.350% Notes Due 2047 247
Celgene Raises USD500 Million in Public Offering of 2.25% Notes Due 2021 248
Celgene Prices Public Offering of 5% Notes Due 2045 for USD2 Billion 249
Celgene Prices Public Offering of 3.55% Notes Due 2022 for USD1 Billion 251
Celgene Prices Public Offering of 2.125% Notes Due 2018 for USD1 Billion 253
Celgene Prices Public Offering of 2.875% Notes Due 2020 for USD1.5 Billion 255
Celgene Prices Public Offering of 3.875% Notes Due 2025 for USD2.5 Billion 257
Celgene Completes Public Offering Of Notes Due 2044 For USD1 Billion 259
Celgene Completes Public Offering Of Notes Due 2019 For USD500 Million 261
Celgene Completes Public Offering Of Notes Due 2024 For USD1 Billion 263
Celgene Completes Public Offering Of Notes Due 2018 For USD 400 Million 265
Celgene Completes Public Offering Of Notes Due 2043 For USD 400 Million 266
Celgene Completes Public Offering Of Notes Due 2023 For USD 700 Million 267
Tengion Completes Private Placement Of Notes Due 2015 For USD 15 Million 268
Celgene Completes Public Offering Of Senior Unsecured Notes Due 2022 For USD 1 Billion 270
Celgene Completes Public Offering Of Senior Unsecured Notes Due 2017 For USD 500 Million 271
Roche Acquires PETE Technology from AbVitro 272
Celgene Acquires Juno Therapeutics for USD9 Billion 273
Celgene Acquires Impact Biomedicines for up to USD7 Billion 275
Celgene to Acquire 5.9% Stake in BeiGene for USD150 Million 276
Celgene Acquires VentiRx Pharma 277
Celgene to Acquire Delinia 278
Celgene Acquires Acetylon Pharma 279
Celgene Acquires EngMab 280
Juno Therapeutics Acquires RedoxTherapies 281
Juno Therapeutics Acquires AbVitro 282
Celgene Acquires Receptos for USD7.2 Billion 283
Juno Therapeutics Acquires X-BODY 285
AstraZeneca May Acquire Juno Therapeutics 286
Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 287
Celgene to Acquire Quanticel Pharma for USD485 Million 288
Juno Therapeutics Acquires ZetaRx BioSciences 289
Celgene To Acquire Stake In PharmAkea Therapeutics 290
Celgene Invests USD 15 Million In Tengion 291
Celgene Completes Acquisition Of Avila Therapeutics 292
Celgene Corp, Key Competitors 293
Celgene Corp, Key Employees 294
Celgene Corp, Other Locations 295
Celgene Corp, Subsidiaries 295
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.